Novo Nordisk stock jumped early Wednesday on a strong first-quarter report on the back of its GLP-1 drugs Wegovy and Ozempic.
Oops, something went wrong
Novo Nordisk stock jumped early Wednesday on a strong first-quarter report on the back of its GLP-1 drugs Wegovy and Ozempic.